|
|
Volumn 7, Issue 13, 2001, Pages 1251-1257
|
|
Preclinical evaluation of new taxoids
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BMS 181681;
BMS 184476;
BMS 185660;
BMS 188797;
CARBOPLATIN;
CARRIER PROTEIN;
CISPLATIN;
DOCETAXEL;
DOXORUBICIN;
GLYCOPROTEIN P;
MULTIDRUG RESISTANCE PROTEIN;
ORTATAXEL;
PACLITAXEL;
RPR 109881 A;
TAXOID;
TXD 258;
UNCLASSIFIED DRUG;
WATER;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BREAST CANCER;
CANCER;
CLINICAL TRIAL;
COMPETITION;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CROSS RESISTANCE;
DRUG BIOAVAILABILITY;
DRUG EFFICACY;
DRUG INFUSION;
DRUG INTERACTION;
DRUG SCREENING;
DRUG SOLUBILITY;
DRUG STRUCTURE;
DRUG SYNTHESIS;
DRUG TOLERABILITY;
HUMAN;
HUMAN CELL;
IN VIVO STUDY;
LUNG CANCER;
MEDICAL LITERATURE;
MOLECULAR RECOGNITION;
MOUSE;
MULTIDRUG RESISTANCE;
NEUTROPENIA;
NONHUMAN;
OVARY CANCER;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
ANIMALS;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
BRIDGED COMPOUNDS;
NEOPLASMS, EXPERIMENTAL;
PACLITAXEL;
TAXOIDS;
|
|
EID: 0034857136
PISSN: 13816128
EISSN: None
Source Type: Journal
DOI: 10.2174/1381612013397465 Document Type: Article |
|
Times cited : (61)
|
|
References (23)
|
